We are pleased to announce that the President and CEO of Stiris Research, Shantal Feltham, is the recipient of the 2019 Women of Excellence Award in Entrepreneurship. This award, presented every 2 years, honours women who have contributed to the growth of their community, and whose accomplishments inspire others to achieve their goals. Shantal’s passion, […]
London, ON – January 14th, 2019 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announced successfully completing enrollment ahead of the Australian biotech’s corporate milestone target on their Phase 1b Open label study in Uveal Melanoma metastatic to liver. The last patient was screened […]
Cambridge, MA – January 7th, 2019 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announce the addition of Glenn Block to its Business Development team. Glenn Block joins the company as the Executive Director, Sales & Marketing and brings 20+ years’ commercial experience in […]
London, ON – May 24, 2018 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the completion of all 10 Closeout Visits (COVs) of North American Investigative Sites who participated in the extension phase of a Phase II Hormone-Refractory Castrate-Resistant Prostate Cancer (HRCPC) study. […]
London, ON – March 23, 2018 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announced the completion of 84 Investigative Site closeout visits (COVs) for a global Phase III trial in Parkinson’s Disease (PD). “We are very proud of our team’s accomplishment and for […]
London, ON – February 22nd, 2018 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announced that they have successfully completed the database lock ahead of schedule for a US client on their global Phase III trial in Parkinson’s disease trial. “Stiris stepped up to […]
London, ON – February 2nd, 2018 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces successfully achieving an Australian biotech’s corporate milestone target of First Patient First Visit (“FPFV”) in their Phase 1b Open label study in Uveal Melanoma metastatic to liver. Stiris is […]
London, ON – November 7th, 2017 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces they have entered into a Master Services Agreement (the “MSA”) with an Australian biotechnology company. Under the terms of the MSA, Stiris is excited to announce that it will […]
London, ON – September 26, 2017 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces that it has completed and closed a US biotechnology company’s Phase II Meniere’s disease study. “Our Canadian sites all achieved great success on this study and allowed the sponsor […]
London, ON – August 17, 2017 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announced its collaboration with a London, ON hospital and Investigator on their North American Phase II Investigator Initiated trial in Frontotemporal Dementia. “Collaborating and working alongside a local medical and […]